Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Drug Risk Evaluation Deputy Avigan Is Gastrointestinal Specialist

Jul 22 2002

• By The Pink Sheet

Related Content

Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?

Apr 15 2002

Celebrex Label Update Has CV Profile Similar To NSAIDs, No New GI Safety

Jun 10 2002

Colorectal Chemopreventives Should Show 30% Adenoma Reduction – Cmte.

Mar 25 2002

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window